A breakthrough novel treatment of combining T regulatory cells and JadiCells to combat synergistic suppression of lung injury and support acceleration of lung regeneration, has been proposed by Therapeutic Solutions International (OTCMKTS:TSOI). The company has disclosed their data and intention to file a patent as well.
After a series of trials, suppression of lung damage was successfully observed in endotoxin and Poly (IC) models after umbilical cord blood T regulatory cells were administered along with JadiCells. A member of the TNF receptor superfamily – GITR (a blockade of it) – also resulted in suppression of synergy, which suggests a molecular mechanism of this interaction.
Dr. James Veltmeyer, Chief Medical Officer of the company, states that this current treatment offers a novel technique of combating lung damage and preventing scarring in the long-term, which is a common symptom in Covid-19 patients. Deposition of scar tissue in functional portions of the lung causes irregular breathing as long as up to 9 months after the infection. Timothy Dixon, President and CEO, says they are still working on experiments to detect other molecular switches that can be used to improve JadiCell activity, and activities of other stem cells too. They are currently preparing to initiate the Phase –III trial on Covid-19 patients that have been green-lit by the FDA.
On Wednesday, TSOI stock fell 1.57% at $0.0657 with more than 11.47 million shares, compared to its average volume of 14.35 million shares. The stock has moved within a range of $0.0606 – 0.0710 after opening the trade at $0.0650.